# Genitourinary Syndrome of Menopause

A practical approach to confirming GSM, excluding competing vulvovaginal and urinary pathology, selecting local therapies, and individualizing treatment for patients with breast cancer or systemic hormone contraindications.

**Clinical question:** How should clinicians diagnose and treat GSM while accounting for urinary symptoms, cancer history, and hormone-related risk?

Updated: 2026-08-24T17:57:23.359555+00:00

## What matters in practice
- Do not attribute bleeding, focal vulvar lesions, purulent discharge, or persistent urinary symptoms automatically to GSM; evaluate alternative gynecologic, dermatologic, infectious, and urinary causes before escalating therapy.
- For bothersome GSM, low-dose vaginal estrogen is minimally absorbed, does not require progestogen for endometrial protection in patients with an intact uterus, and can be considered when systemic menopausal hormone therapy is contraindicated. [9]
- Local vaginal estrogen can improve dysuria, urinary frequency, urgency, and recurrent urinary tract infections; systemic menopausal hormone therapy may worsen urinary incontinence. [14]
- In breast cancer survivors, start with nonhormonal moisturizers and lubricants; persistent moderate-to-severe symptoms require individualized discussion of vaginal estrogen or other options with attention to tumor biology and oncology treatment. [3][14][16]
- Do not offer vaginal laser or radiofrequency as established replacement therapy for GSM; randomized evidence remains limited, and sham-controlled trials have reported procedure-related adverse effects without a clear safety or efficacy advantage. [16][21]

## Confirm GSM while identifying findings that require a different workup

Treat empirically only when the clinical pattern is concordant and no alarm feature is present.

GSM is a clinical syndrome encompassing vulvovaginal and lower urinary tract symptoms associated with estrogen deficiency; the symptom cluster may include dryness, burning, irritation, dyspareunia, dysuria, urgency, and recurrent urinary tract infections. [10][16] At the first visit, document the dominant domain—penetrative pain, vulvar burning, urinary urgency/dysuria, recurrent culture-confirmed UTI, or mixed symptoms—because treatment response and competing diagnoses differ by domain.

Perform a focused vulvar, vaginal, and pelvic examination when symptoms are new, severe, refractory, or accompanied by bleeding, discharge, focal pain, or a visible lesion. A lesion, erosive process, marked architectural change, purulent discharge, abnormal uterine bleeding, or a palpable pelvic mass should redirect evaluation toward vulvar dermatosis or neoplasia, vaginitis or sexually transmitted infection, cervical/endometrial pathology, pelvic floor dysfunction, or bladder disease rather than escalation of GSM therapy.

For dysuria, urgency, or recurrent UTI, obtain urinalysis and urine culture when infection is clinically plausible; do not label persistent urinary symptoms as estrogen deficiency after a negative or discordant infectious evaluation without reassessing the pelvic examination and bladder differential. Urinary complaints during menopause have multiple contributors and are not all attributable solely to estrogen deficiency. [14]
- Escalate abnormal uterine or postmenopausal bleeding to a bleeding evaluation before prescribing vaginal hormone therapy. [7]
- Biopsy or refer a persistent focal vulvar lesion, ulcer, pigment change, or unexplained architectural distortion rather than treating repeatedly as GSM.
- Review prior pelvic radiation, antiestrogen therapy, chemotherapy-induced menopause, endocrine therapy adherence, and sexual pain history; cancer treatments, tamoxifen, and aromatase inhibitors can intensify hypoestrogenic genital symptoms. [16]

*Clinical pattern determines the next diagnostic step.*

| Presentation | Interpretation | Next action |
| --- | --- | --- |
| Dryness, burning, dyspareunia with compatible examination | GSM is likely when symptoms and examination are concordant. [10][16] | Begin symptom-directed nonhormonal or local therapy; reassess response. |
| Dysuria, urgency, recurrent UTI symptoms | May reflect GSM, infection, overactive bladder, or another urinary disorder; menopause alone does not explain all urinary symptoms. [14] | Use urinalysis and culture when UTI is plausible; reassess if symptoms persist after infection is excluded or treated. |
| Bleeding, purulent discharge, focal lesion, ulcer, or mass | Not a routine GSM presentation. | Perform targeted gynecologic, infectious, dermatologic, or oncologic evaluation before attributing symptoms to GSM. |

## Match treatment intensity to symptom severity and treatment goals

Choose a vaginal therapy for isolated GSM; do not use systemic therapy solely when local treatment meets the goal.

For mild symptoms or for patients avoiding hormones, use vaginal moisturizers on a regular schedule and lubricants with sexual activity. In breast cancer survivors, these nonhormonal options are generally the initial approach, but their benefit is typically mild and short term. [16] Reassess the specific symptom driving distress—dyspareunia, dryness, burning, or urinary symptoms—rather than continuing an ineffective product indefinitely.

For persistent bothersome GSM, low-dose vaginal estrogen is an effective local option delivered as cream, tablet, insert, suppository, or local silicone ring. [7][9] Low-dose vaginal estrogen is minimally absorbed and does not require concomitant progesterone in patients with an intact uterus. [9] Verify that a vaginal ring is a local low-dose product rather than a systemically delivering ring before prescribing. [7]

Use systemic menopausal hormone therapy only when there is a separate systemic indication, such as vasomotor symptoms or prevention of bone loss and fracture risk, and then account for uterine status and cardiovascular/thrombotic risk. [9] Estrogen alone in a patient with an intact uterus increases endometrial hyperplasia and cancer risk and should be paired with a progestin or an endometrial-protective SERM strategy when systemic therapy is used. [9] Oral formulations are associated with hypertriglyceridemia, venous thromboembolism, and elevated high-sensitivity C-reactive protein; observational data suggest transdermal estrogen may carry less venous thromboembolism and stroke risk than oral estrogen. [9]
- For isolated vaginal symptoms, prefer a low-dose local vaginal product over systemic menopausal hormone therapy. [7][9]
- Ask at follow-up whether urinary urgency, dysuria, frequency, or culture-confirmed UTI burden has changed; localized vaginal estrogen has demonstrated benefit for these urinary manifestations. [14]
- If symptoms persist despite correct and consistent use, repeat the examination and reconsider pelvic floor, dermatologic, infectious, bladder, or pain-related contributors before changing treatment class.

*Therapy selection for GSM by clinical context.*

| Clinical context | Preferred next step | Key limitation or safeguard |
| --- | --- | --- |
| Mild dryness or intercourse-related discomfort | Regular vaginal moisturizer plus lubricant with sexual activity. [16] | Expect primarily mild, short-term symptom relief. [16] |
| Persistent bothersome isolated GSM | Low-dose vaginal estrogen by cream, tablet, insert, suppository, or local ring. [7][9] | Confirm local rather than systemic ring formulation. [7] |
| Intact uterus receiving low-dose vaginal estrogen | No concomitant progestogen is required. [9] | Evaluate unexplained vaginal bleeding rather than assuming a local-treatment effect. [7] |
| Systemic vasomotor symptoms plus GSM | Consider systemic menopausal hormone therapy only after individualized risk assessment; add endometrial protection if uterus is intact. [9] | Oral therapy has hepatic first-pass-associated metabolic and thrombotic tradeoffs. [9] |
| Urinary urgency, dysuria, frequency, or recurrent UTI associated with GSM | Consider localized vaginal estrogen after appropriate urinary assessment. [14] | Do not assume all urinary symptoms are caused by estrogen deficiency. [14] |

## Use prasterone or ospemifene selectively, not as interchangeable substitutes

Alternative agents are most useful when local estrogen is ineffective, unsuitable, unavailable, or unacceptable.

Vaginal prasterone (dehydroepiandrosterone) is an alternative pharmacologic option when nonhormonal products or vaginal estrogen are ineffective or unsuitable. [14] It may be particularly relevant when a patient cannot tolerate a local estrogen formulation, but treatment selection in cancer survivors remains individualized because robust safety data in gynecologic cancer survivors are limited. [14]

Oral ospemifene is a selective estrogen receptor modulator and the only FDA-approved oral treatment for GSM. [17] It may be useful when local therapy cannot be tolerated or accessed, including situations such as post-radiation vaginal stenosis, but its systemic exposure and limited safety data in gynecologic cancer survivors require a different risk discussion from low-dose vaginal estrogen. [14]

Avoid presenting energy-based vaginal devices as equivalent to established medical therapies. CO2 laser and radiofrequency have been studied, including randomized sham-controlled trials, but evidence remains uncertain; in breast cancer survivor trials, pain during treatment was common and one trial reported adverse effects in 37% of laser-treated participants versus 27% of sham-treated participants, without differences in incidence or severity. [16][21]
- Consider vaginal prasterone when nonhormonal therapy and vaginal estrogen are ineffective or unsuitable. [14]
- Consider oral ospemifene when a patient cannot use or obtain local treatment, while recognizing its systemic SERM exposure. [14][17]
- Reserve laser or radiofrequency for research-oriented or carefully counseled settings, not as routine first-line or replacement treatment. [16][21]

*Nonestrogen and device-based options have distinct practical roles.*

| Option | Potential role | Decision-limiting issue |
| --- | --- | --- |
| Vaginal prasterone | Alternative when nonhormonal therapy or vaginal estrogen is ineffective or unsuitable. [14] | Safety evidence is limited in gynecologic cancer survivors. [14] |
| Oral ospemifene | Oral FDA-approved GSM treatment when local therapy is not tolerated or accessible. [14][17] | Systemic SERM exposure and limited cancer-survivor safety data require individualized selection. [14] |
| CO2 laser or radiofrequency | Not established as routine therapy. [16][21] | Sham-controlled evidence and procedure-related adverse effects do not support substituting it for established treatments. [16][21] |

## Individualize GSM therapy in breast cancer survivors and patients with systemic hormone contraindications

Separate local GSM treatment decisions from systemic hormone therapy decisions.

Breast cancer survivors often have more severe vulvovaginal atrophy and symptom burden than postmenopausal women without breast cancer; chemotherapy, tamoxifen, and aromatase inhibitors can worsen the hypoestrogenic genital environment. [16] Ask whether symptoms threaten sexual function, sleep, urinary health, or adherence to adjuvant endocrine therapy, because the severity of functional impact determines whether limited nonhormonal relief is acceptable.

Begin with nonhormonal moisturizers and lubricants in breast cancer survivors. [16] For persistent moderate-to-severe GSM, vaginal estrogen may be considered after individualized assessment and, when appropriate, discussion with the oncology team; decisions should account for cancer type, tumor biology, current endocrine therapy, symptom severity, and patient priorities. [3][14]

Do not extrapolate the low systemic absorption of local therapy to systemic menopausal hormone therapy. In patients with an intact uterus, systemic estrogen requires endometrial protection; oral systemic formulations also carry first-pass-associated hypertriglyceridemia and venous thromboembolism tradeoffs. [9] In patients with prior spontaneous coronary artery dissection, reassess the indication for systemic hormone therapy and discontinue it unless there is a compelling reason to continue; recurrent GSM after stopping systemic therapy can prompt coordinated consideration of local treatment. [6]
- Document the specific breast cancer treatment—tamoxifen, aromatase inhibitor, chemotherapy, radiation, or none—before selecting hormonal therapy. [16]
- Use shared decision-making for persistent symptoms in hormone-sensitive cancer survivors; involve oncology when the decision could affect endocrine therapy or perceived recurrence risk. [3][14]
- Distinguish local low-dose vaginal therapy from systemic estrogen products at every medication reconciliation. [7][9]

*Escalation framework for GSM in breast cancer survivorship.*

| Clinical scenario | Management direction | Required decision point |
| --- | --- | --- |
| Mild symptoms | Moisturizer and lubricant first. [16] | Assess whether relief is sufficient and whether symptoms affect endocrine therapy adherence. |
| Persistent moderate-to-severe symptoms | Consider vaginal estrogen after individualized assessment; consider oncology discussion when appropriate. [3][14] | Account for tumor biology, endocrine therapy, severity, and patient priorities. [14] |
| Local estrogen ineffective or unsuitable | Consider vaginal prasterone or oral ospemifene selectively. [14][17] | Discuss limited cancer-survivor safety data, particularly for gynecologic cancer survivors. [14] |
| Considering systemic menopausal hormone therapy | Treat as a separate systemic-risk decision, not a default escalation for local GSM. [9] | Assess uterine status and cardiovascular/thrombotic risks; provide endometrial protection if uterus is intact. [9] |

## Monitor symptom-specific benefit and investigate nonresponse

The endpoint is functional improvement, not normalization of examination findings alone.

At follow-up, measure the outcome that prompted treatment: pain with penetration, dryness/burning, urinary urgency or dysuria, frequency of culture-confirmed UTI, and ability to continue cancer-directed endocrine therapy. For urinary presentations, improvement with localized estrogen supports a GSM contribution, but persistent symptoms still warrant reassessment because urinary symptoms have multifactorial causes. [14]

Re-examine patients with persistent pain, recurrent bleeding, new discharge, lesion development, or no meaningful benefit after an adequate treatment trial. Nonresponse should trigger reconsideration of vulvar dermatoses, infection, pelvic floor dysfunction, painful bladder conditions, structural disease, medication effects, or malignancy rather than serial empiric treatment changes.

For patients receiving systemic menopausal hormone therapy for an independent indication, reassess route and ongoing indication periodically. Transdermal treatment may be preferable to oral therapy for patients with moderate cardiovascular risk because available observational evidence suggests lower venous thromboembolism and stroke risk, although large randomized comparisons are lacking. [9]
- Stop and evaluate new unexplained vaginal bleeding before further hormonal escalation. [7]
- Repeat urinalysis and culture for recurrent dysuria or UTI-like symptoms when infection remains plausible.
- Refer persistent focal vulvar findings for diagnostic evaluation rather than repeated treatment for presumed GSM.

*Failure of symptom-directed treatment should change the diagnostic plan.*

| Follow-up finding | Interpretation | Next step |
| --- | --- | --- |
| Meaningful improvement in vaginal and/or urinary symptoms | Current treatment is addressing a GSM component. [14] | Continue the effective strategy and monitor symptom-specific function. |
| Persistent urinary symptoms despite treatment | GSM may be incomplete or not the principal cause; urinary symptoms are multifactorial. [14] | Reassess with urinalysis/culture when indicated and evaluate alternative bladder or pelvic causes. |
| Persistent focal pain, lesion, discharge, or bleeding | Features are not explained adequately by uncomplicated GSM. | Repeat examination and pursue targeted gynecologic, dermatologic, infectious, or oncologic evaluation. |
| No benefit from correctly used nonhormonal therapy | Symptom burden may require local pharmacologic therapy or an alternate diagnosis. | Consider low-dose vaginal estrogen when appropriate, or selective alternatives such as prasterone or ospemifene. [9][14][17] |

## References
1. Genitourinary syndrome of menopause among breast cancer ... — gocm.bmj.com — https://gocm.bmj.com/content/gocm/5/3/e000089.reviewer-comments.pdf
2. BMJ Open is committed to open peer review. As ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/bmjopen/15/11/e104711.draft-revisions.pdf
3. a randomised clinical trial protocol comparing multimod — bmjopen.bmj.com — https://bmjopen.bmj.com/content/bmjopen/15/11/e104711.full.pdf
4. Genitourinary syndrome of menopause induced by breast ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/15/11/e104711
5. An empowerment model for managing menopause - The Lancet — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2902799-X/fulltext
6. Spontaneous Coronary Artery Dissection: Current State of ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/cir.0000000000000564
7. Menopause Hormone Therapy After Spontaneous Coronary Artery Dissection: A Gap in the Literature — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2026.102641
8. Should This Patient Receive Hormone Therapy for Her ... — annals.org — https://annals.org/doi/10.7326/M17-3320
9. Improving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2025.101791
10. CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1743609521008304
11. CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1743609521008304
12. Revitalizing research in genitourinary syndrome of menopause — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002937818322798
13. The 2020 genitourinary syndrome of menopause position... : Menopause — journals.lww.com — https://journals.lww.com/menopausejournal/fulltext/2020/09000/the_2020_genitourinary_syndrome_of_menopause.5.aspx
14. Menopausal hormone therapy and comprehensive ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.71188
15. Genitourinary syndrome of menopause (GSM) — academic.oup.com — https://academic.oup.com/smr/article/14/1/qeaf055/8261468
16. Laser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial - Serquiz - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/ijgo.70665
17. Genitourinary Syndrome of Menopause - Marino - 2021 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jmwh.13277
18. Impact of Vaginal Estradiol on the Genitourinary Syndrome of ... — academic.oup.com — https://academic.oup.com/cid/article/82/4/e710/8373761
19. Physical methods for the treatment of genitourinary syndrome ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.13561
20. FDA Boxed Warning Removal on Menopause Hormone ... — agsjournals.onlinelibrary.wiley.com — https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.70256
21. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause — www.auajournals.org — https://www.auajournals.org/doi/10.1097/JU.0000000000004589
22. Abbreviations and Acronyms - Genitourinary Syndrome of Menopause: A Systematic Review - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK609623
23. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause | Journal of Urology — www.auajournals.org — https://www.auajournals.org/doi/full/10.1097/JU.0000000000004589
24. References - Genitourinary Syndrome of Menopause: A Systematic Review - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK609636

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.